Location History:
- Sodertalje, SE (2010)
- Södertälje, SE (2011)
Company Filing History:
Years Active: 2010-2011
Title: Erwan Arzel: Innovator in Pharmaceutical Compounds
Introduction
Erwan Arzel is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that exhibit activity at metabotropic glutamate receptors. With a total of two patents to his name, Arzel's work is recognized for its potential therapeutic applications.
Latest Patents
Arzel's latest patents include innovative compounds that contain tetrazolyl and triazolyl rings. These compounds, along with their pharmaceutically acceptable salts, hydrates, and enantiomers, are useful in exhibiting activity at metabotropic glutamate receptors. Another significant patent involves novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives. This invention not only covers the structural formula of these compounds but also their therapeutic uses, particularly in imaging amyloid deposits in living patients. This advancement is crucial for the antemortem diagnosis of Alzheimer's disease and for measuring the clinical efficacy of therapeutic agents aimed at treating this condition.
Career Highlights
Erwan Arzel is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on the development of innovative pharmaceutical solutions that address critical health challenges. His contributions have been instrumental in advancing the understanding and treatment of various neurological conditions.
Collaborations
Arzel has collaborated with notable colleagues, including Louise G Edwards and Methvin Benjamin Isaac. These collaborations have further enriched his research and development efforts in the pharmaceutical domain.
Conclusion
Erwan Arzel stands out as a significant figure in the field of pharmaceutical innovation. His patents reflect a commitment to advancing medical science and improving patient outcomes. His work continues to inspire future developments in the industry.